Kopfbereich

papildus pārlūkošana

Logo

Jūs esat šeit:

AOP jaunumu nodaļa


Preses istaba

Šī mājas lapas sadaļa sniedz vispārīgo informāciju par AOP Orphan. Mūsu sabiedrisko attiecību speciālists ar prieku atbildēs uz Jūsu jautājumiem vai komentāriem:

Modestas Jocius
AOP Orphan Pharmaceuticals AG Baltijas valstu pārstāvniecība
Didžioji, 25, LT-01128, Viļņa
Tālr.: +370 672 12222
Fakss: +370 5 2755203
modestas.jocius(at)aoporphan.com

AOP Orphan Pharmaceuticals AG, the Austrian specialist for rare diseases, will implement ‘Mobile IntelligenceTM (MI)’ - the smart CRM Tool from leading Life-Sciences consultant, IQVIA.

Bioprojet Pharma SAS and AOP Orphan Pharmaceuticals AG (AOP Orphan) entered a distribution agreement for Wakix®The covered territory includes mainly Central and Northern European countriesWakix® is approved for treatment of...

AOP Orphan supports the Christian Doppler Laboratory for Iron Metabolism and Anemia Research at the Medical University of Innsbruck, Austria, opening on January 31st, 2018. To read the full press release in German, please click...

Uzņēmums AOP Orphan Pharmaceuticals AG šodien ir paziņojis, ka tam ir izdevies iegūt selisistatu – ļoti selektīvu SIRT1 inhibitoru, kura eksperimentālajos pētījumos ir novērotas iespējamas slimību modificējošas īpašības, kas var...

An interview with Dr Rudolf Widmann, CEO and Dr Christoph Klade, CSO about the current status of Vienna, Austria as a Research & Development base, its specifics, hurdles and chances,  which was published recently in...

AOP Orphan Pharmaceuticals AG (AOP Orphan) šodien paziņoja, ka viņu izplatīšanas partneris Amomed Pharma GmbH (Amomed) 19. jūnijā sāk RAPIBLOC® (Rapibloc, 300 mg pulveris infūziju šķīduma pagatavošanai) komercializēšanu, kas...

Nesen Austrijas laikraksta “derStandard” īpaši izdotā pielikumā “CURE” publicēta intervija ar ģenerāldirektoru Dr. Rūdolfu Vidmanu (Widmann) un zinātnes attīstības direktoru Dr. Kristofu Klādi (Klade) par “AOP Orphan” apņemšanos...

Highlights: Ultra-short acting and highly cardio-selective beta blocker Rapibloc® (Landiolol) receives regulatory approval in Europe.Rapibloc® (Landiolol) allows rapid control of heart rate with a straightforward dosing scheme...

As an easy-to-use and highly reliable inhalation powder, the antipsychotic ADASUVE® has revolutionized the treatment of agitation in patients suffering from schizophrenia or bipolar disorder. This was also confirmed by experts...

The Austrian pharmaceutical company AOP Orphan, which specialises in rare diseases and innovative therapies, will in future market the antiarrhythmic drug BRINAVESS®, developed by Cardiome Pharma Corp., Canada, in Central Europe....

The Austrian pharmaceutical company AOP Orphan is a European pioneer in the field of rare diseases. Industry expert Hans Peter Hasler (58) joined AOP Orphan’s Supervisory Board at the beginning of the year. The Swiss native...

AOP Orphan and Ferrer Internacional are expanding their long-standing partnership to include the marketing of the anti-psychotic drug Adasuve® (Staccato® Loxapine) in Central and Eastern Europe.